Teva Challenges Shire's Adderall XR Patent

Law360, New York (February 23, 2005, 12:00 AM EST) -- Israeli generics maker Teva Pharmaceuticals has initiated a challenge against the patent rights to U.K. drug maker Shire Pharmaceuticals Group PLC’s blockbuster anti-hyperactivity treatment Adderall XR.

Shire said Tuesday it had received a Paragraph IV Notice letter from Teva Pharmaceuticals USA Inc., advising of the filing of an abbreviated new drug application (ANDA) for its amphetamine combination product, a generic version of Shire's mixed amphetamine salts product, Adderall XR.

Shire received previously Paragraph IV Notice letters from Barr Laboratories Inc., Impax Laboratories Inc. and Colony Pharmaceuticals...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.